Manufacturing Technician 2

Hologic's Fluent(R) Pro system wins International Design Excellence Award for user-centric innovation in women's health. September 4, 2026 Technology honored for design that helps simplify fluid management and visualization during hysteroscopic procedures MARLBOROUGH, Mass. - Hologic, a global leader in women's health, has been honored with an International Design Excellence Award (IDEA) for its Fluent Pro fluid management system, which supports visualization and fluid control during hysteroscopy. "This award reflects our team's dedication to thoughtful design, clinical partnership and continuous innovation," said Brandon Schnittker, CEO, GYN Surgical Solutions. "Our goal has always been to help serve more patients while continuing to meet the evolving needs of our customers. The Fluent Pro system is a strong example of how purposeful, user-centric design can make complex procedures feel simpler and more intuitive for the teams who rely on our technologies every day." Presented annually by the Industrial Designers Society of America (IDSA), one of the longest-standing and largest industrial design associations in existence, the International Design Excellence Awards recognize design excellence across industries and disciplines. This year the organization received more than 2,000 entries. The Fluent Pro system is designed to deliver seamless integration and an intuitive user experience that supports procedural performance, including during procedures that use the MyoSure(R) tissue removal system, a device that removes fibroids and polyps through hysteroscopy. The user interface provides setup, operation and troubleshooting help screens that are easily accessible throughout the procedure. The system also provides suction control to resect simple to complex types of pathology designed for improved MyoSure procedures. The Fluent Pro interface aims to support the broader operating room team, including physicians performing procedures and nursing staff coordinating setup and room flow. Its user-centric design reflects the realities of the clinical environment, helping physicians stay focused on patient care and procedural execution. The system is also designed to simplify workflows and help teams operate with greater consistency and confidence. More than 1,020 hospital systems across the United States use the Fluent Pro system, allowing clinical teams nationwide to benefit from this award-winning technology. About Hologic, Inc. Hologic, Inc. is a global leader in women's health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn, Facebook, X, Instagram and YouTube. Forward-Looking Statements This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based. Hologic, Fluent and MyoSure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. Notes and Disclaimers Important Safety Information The Fluent(R) Pro fluid management system is intended to provide liquid distension of the uterus during diagnostic and operative hysteroscopy, and to monitor the volume differential between the irrigation liquid flowing into and out of the uterus while providing drive, control and suction for hysteroscopic morcellators, specifically for the MyoSure(R) tissue removal device. The Fluent Pro fluid management system may not be used to introduce fluids into the uterus when hysteroscopy is contraindicated. The system should not be used to remove pathologies from pregnant patients or patients exhibiting pelvic infection, cervical malignancies, or previously diagnosed endometrial cancer. For detailed benefit and risk information, please consult the Instructions For Use. Media Contact: Bridget Perry Senior Director, Corporate Communications (+1) 508.263.8654 [email protected]

AI Cytology Screening market growth and challenges through 2033. Significant growth is on the horizon for the AI in cytology screening device market, with projections indicating an increase to over USD 330 million by 2033 as healthcare systems seek efficient diagnostic solutions. Key facts. * AI in cytology market projected to grow from $122.6M in 2026 to $330.9M by 2033 (CAGR 15.2%). * North America leads with 39.9% market share; Asia Pacific fastest-growing region indicates shifts. * High implementation costs hinder adoption in smaller labs, revealing vulnerability in market access. * Hologic's FDA approval for Genius system enhances competitive positioning in cervical cancer diagnostics. * Cloud-based solutions expected to grow rapidly, indicating strategic shift towards scalable AI technologies. Summary. The AI in cytology screening device market is poised for significant growth, projected to expand from USD 122.6 million in 2026 to USD 330.9 million by 2033, reflecting a compound annual growth rate (CAGR) of 15.2%. This growth is primarily driven by the increasing demand for improved diagnostic accuracy in the face of a global shortage of skilled cytologists. As healthcare providers seek to enhance laboratory efficiency and reduce the manual workload, the integration of artificial intelligence into cytology screening is becoming a critical strategy. North America currently leads the market, accounting for 39.9% of revenue share in 2025, with the U.S. being the largest contributor. The region's dominance is attributed to its robust research and development infrastructure, favorable reimbursement policies, and a high concentration of healthcare facilities equipped to adopt advanced technologies. Meanwhile, the Asia Pacific region is expected to experience the fastest growth, indicating a shift in market dynamics as emerging economies ramp up investments in healthcare technologies. The market is segmented into various product categories, with automated cytology screening systems holding a 33.7% revenue share in 2025. These systems leverage AI to automate the analysis of digitized slides, enhancing the speed and accuracy of abnormal cell detection. The gynecological cytology screening application is particularly significant, representing 75.6% of the market due to the ongoing emphasis on cervical cancer screening initiatives. Hospitals are the primary end-users, comprising 40.6% of the market, reflecting their critical role in implementing these technologies. The rising volume of cervical cancer screenings and preventive healthcare initiatives is intensifying the workload for pathology laboratories, which are often constrained by a lack of qualified specialists. This gap is driving investments in AI-assisted cytology solutions that can boost productivity and maintain diagnostic quality. For example, Hologic's Genius Digital Diagnostics System, which received FDA clearance, exemplifies how AI can enhance diagnostic workflows by automating slide evaluation and prioritizing high-risk cases for expert review. Despite the promising outlook, the market faces challenges, particularly the high implementation costs associated with transitioning to AI-enabled systems. Healthcare providers must invest in advanced imaging technologies, data storage solutions, and workforce training, which can be particularly burdensome for smaller institutions. This financial barrier limits the widespread adoption of AI technologies, especially in resource-constrained environments. The competitive landscape is characterized by ongoing innovation and strategic collaborations. Companies are focusing on expanding their product offerings to create integrated diagnostic solutions that address both workforce shortages and operational inefficiencies. The recent partnership between Synergy Laboratories and Hologic to implement AI-driven cervical cytology screening is a case in point, highlighting the growing commercial viability of these technologies. As the market evolves, the integration of AI into routine cytology practices is expected to accelerate. The demand for digital pathology solutions that facilitate remote consultations and centralized diagnostic services is increasing. This trend is likely to enhance the accessibility of advanced diagnostic technologies, particularly as cloud-based platforms become more prevalent. Looking ahead, the sustained emphasis on early cancer detection and the expansion of cervical cancer screening programs will create substantial opportunities for AI in cytology screening. Healthcare providers are increasingly prioritizing intelligent diagnostic solutions that can optimize testing capacity and improve the quality of diagnostic services. As regulatory approvals continue to support innovation, the market is set for robust growth, with AI-enabled cytology screening devices playing a pivotal role in transforming diagnostic workflows across global healthcare systems. The focus on developing scalable, integrated solutions will be critical for companies aiming to capitalize on this expanding market. Entities mentioned. Synergy Laboratories Aiforia Technologies Blackstone Genius Digital Diagnostics System Genius Cervical AI Aptima HPV Assay Technologies artificial intelligence deep learning digital pathology whole-slide imaging automated cytology screening systems AI cytology analysis software Organizations Key concepts. AI in cytology screening market growth diagnostic accuracy workforce shortages digital pathology integration cervical cancer screening automated slide evaluation regulatory impact Definitions. * AI in Cytology Screening - The use of artificial intelligence technologies to enhance the efficiency and accuracy of cytology diagnostics. * Automated Cytology Screening Systems - Systems that utilize AI to automate the analysis of cytological samples, improving diagnostic workflows. * Digital Pathology - The management and interpretation of pathology information in a digital format, facilitating remote consultations and integrated workflows. * Whole-Slide Imaging - A technology that captures high-resolution images of entire microscope slides, enabling digital analysis and storage. * Cervical Cancer Screening - The process of testing for cervical cancer in women, often using Pap smears and HPV testing. Use cases. * | Enhancing cervical cancer screening accuracy * | Automating routine cytology diagnostics * | Improving laboratory efficiency * | Facilitating remote consultations * | Optimizing specialist productivity * | Supporting workflow in pathology laboratories Frequently asked questions. What is driving the growth of AI in cytology screening? The growth is primarily driven by a shortage of skilled cytologists, increasing cervical cancer screening volumes, and the need for improved diagnostic accuracy and laboratory efficiency. How does AI improve diagnostic accuracy in cytology? AI enhances diagnostic accuracy by automating the analysis of digitized slides, prioritizing high-risk cases, and reducing the burden of manual evaluations, allowing specialists to focus on complex cases. What are the challenges in adopting AI-enabled cytology solutions? Challenges include high implementation costs, the need for robust digital pathology infrastructure, and the requirement for ongoing investments in training and regulatory compliance. What role do regulatory bodies play in the AI cytology market? Regulatory bodies like the U.S. FDA ensure the safety, performance, and clinical validation of AI-enabled diagnostic systems, fostering innovation and market confidence. What future trends are expected in the AI in cytology screening market? Future trends include increased integration of AI with digital pathology, expansion of cervical cancer screening programs, and advancements in cloud-based AI technologies to enhance diagnostic workflows.